In one of these studies, which involved 93 patients with EGFR‐mutant lung adenocarcinoma, patients with T790M (n = 58, 62%) had better post‐progression survival (median survival, 19 vs. 12 months; p = 0.036) than T790M‐negative patients.16 The gene discussed is EGFR; the disease is lung adenocarcinoma.